Overview
Q1 2020
Quarterly Results
Mar 31, 2020
Price
Change
MKT Cap
Volume
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others. Corbus expects data from its Phase 1 safety study in 2020.
Sign up for email alerts
Be the first to receive breaking news
Sign up today
Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus
View Full Bio
Craig Millian, MBA
Chief Commercial Officer
Craig Millian joined Corbus as Chief Commercial Officer in February 2019. Mr. Millian brings 25 years of experience leading commercial organizations for a range of pharmaceutical companies as well as a successful track record building
View Full Bio
Sean Moran, CPA, MBA
Chief Financial Officer
Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery, and medical device companies. Mr. Moran has successfully managed operations from start
View Full Bio
Barbara White, M.D.
Chief Medical Officer and Head of Research
Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and
View Full Bio
Robert Discordia, Ph.D.
Chief Operating Officer
Robert Discordia, Ph.D., joined Corbus in May 2018. Dr. Discordia brings to Corbus more than 25 years of biopharmaceutical industry experience in CMC development and business operations. Prior to joining the Company, Dr. Discordia was
View Full Bio
Ross Lobell
Vice President, Regulatory Affairs
Ross Lobell joined Corbus as Vice President, Regulatory Affairs in April 2018. Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory
View Full Bio
Alan Holmer
Chairman of the Board
Alan F. Holmer served from 1996 to 2005 as President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents the worldwide interests of leading pharmaceutical and
View Full Bio
Avery W. Catlin previously served as Senior Vice President, Chief Financial Officer, and Secretary of Celldex Therapeutics, Inc., a public biopharmaceutical company. Prior to joining Celldex Therapeutics, Inc. in January 2000, he served as
View Full Bio
Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus
View Full Bio
David Hochman is a Managing Partner of Orchestra Medical Ventures, an investment firm that employs an innovative strategy to create, build and invest in medical technology companies intended to generate substantial clinical value and
View Full Bio
Rachelle Jacques
Director
Ms. Jacques is the Chief Executive Officer of Enzyvant Therapeutics, Inc, a private biopharmaceutical company focused on developing therapies for patients with rare diseases. Previously, beginning in 2017, she served as the Senior Vice
View Full Bio
John Jenkins, M.D.
Director
Dr. Jenkins served as the Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, where he was responsible for more than 1,000 agency
View Full Bio
Pete Salzmann, M.D., MBA
Director
Dr. Salzmann has served as the Chief Executive Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, since June 2019, and as a member
View Full Bio
